Dr. Nagarathna G. Manjappa, MD

Dr. Manjappa practices at U.S. Renal Care Napa Dialysis in Petaluma, California.

Dr. Manjappa's NPI, 1710093349, was assigned on August 23, 2006. Dr. Manjappa graduated from Bangalore Medical College in 2000. Dr. Manjappa's California license number on file is A118723.

Dr. Manjappa's primary practice is U.S. Renal Care Napa Dialysis, at 2100 S McDowell Blvd, Petaluma, CA 94954 in Sonoma County. The practice phone is (707) 501-5301.

Dr. Manjappa's primary practice is U.S. Renal Care Napa Dialysis in Petaluma, California. Dr. Manjappa is also affiliated with Adventist Health Clear Lake. The medical group on file is Associated Kidney Specialists of the North Bay. Dmand AI also links Dr. Manjappa to 4 more hospitals, 3 dialysis centers, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Manjappa practices, 10 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Manjappa's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Manjappa is board certified in nephrology by the American Board of Internal Medicine. Dmand AI has Dr. Manjappa's licenses on file in 8 states: California, Florida, Georgia, Indiana, South Carolina, Kentucky, Texas and Tennessee.

Dmand AI lists acute kidney failure, chronic anemia, chronic kidney disease, fluid and electrolyte imbalances, hypercalcemia, kidney cysts and kidney disease among the conditions Dr. Manjappa treats.

CMS data shows 2,279 Medicare services from Dr. Manjappa across 11 procedure codes in 2024, for 774 Medicare patients. Medicare paid $301,642 for them.

CMS counts 774 Medicare patients who saw Dr. Manjappa in 2024. The largest group is 75 to 84, with 303 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 41% are also on Medicaid. Their average risk score is 2.77, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Manjappa's median patient age at 72, with 42% women.

In 2024, Dr. Manjappa wrote 2,168 Medicare Part D claims for 348 patients. 69% of them were for generic drugs. CMS names the drug for 1,954 of them, across 40 drugs with 11 or more claims each, at $644,567 in total drug cost. In 2023, CMS named 2,112 claims across 45 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Dr. Manjappa for performance year 2024, reported as part of a group. Dr. Manjappa accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Manjappa as offering telehealth.

Dmand AI links 6 papers to Dr. Manjappa, published from 2003 to 2011. The most frequent topics are Angioplasty, Balloon, Coronary, Apoptosis and Cells, Cultured. Dr. Manjappa has published most often in J Invasive Cardiol. Dr. Manjappa's most frequent co-authors are Noosha Baqi, MD, Robert Henry Barth, MD and Philip Goldwasser, MD.

CMS Open Payments shows 164 general payments to Dr. Manjappa from 23 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 71% of the total. AstraZeneca Pharmaceuticals LP paid the most, $2,512.

Dmand AI lists 1 award for Dr. Manjappa.

Dr. Manjappa graduated from Bangalore Medical College in 2000. Dr. Manjappa is a member of ASN.

Dr. Manjappa is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.